Immediate Administration of Tolvaptan Prevents the Exacerbation of Acute Kidney Injury and Improves the Mid-Term Prognosis of Patients With Severely Decompensated Acute Heart Failure
-
- Shirakabe Akihiro
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Hata Noritake
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Yamamoto Masanori
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Kobayashi Nobuaki
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Shinada Takuro
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Tomita Kazunori
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Tsurumi Masafumi
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Matsushita Masato
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Okazaki Hirotake
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Yamamoto Yoshiya
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Yokoyama Shinya
- Division of Intensive Care Unit, Chiba Hokusoh Hospital, Nippon Medical School
-
- Asai Kuniya
- Department of Cardiovascular Medicine, Nippon Medical School
-
- Shimizu Wataru
- Department of Cardiovascular Medicine, Nippon Medical School
この論文をさがす
抄録
Background: Tolvaptan, an oral selective vasopressin 2 receptor antagonist that acts on the distal nephrons to cause a loss of electrolyte-free water, is rarely used during the acute phase of acute heart failure (AHF). Methods and Results: We investigated 183 AHF patients admitted to the intensive care unit and administered tolvaptan (7.5mg) with continuous intravenous furosemide, and then additionally at 12-h intervals until HF was compensated. When intravenous furosemide was changed to peroral use, the administration of tolvaptan was stopped. The patients were assigned to tolvaptan (n=52) or conventional treatment (n=131) groups. The amount of intravenous furosemide was significantly lower (35.4 [16.3–56.0] mg vs. 80.0 [30.4–220.0] mg), the urine volume was significantly higher on days 1 and 2 (3,691 [3,109–4,198] ml and 2,953 [2,128–3,592] ml vs. 2,270 [1,535–3,258] ml and 2,129 [1,407–2,906] ml) and the numbers of patients with worsening-AKI (step-up RIFLE Class to I or F) and Class F were significantly fewer (5.8% and 1.9% vs. 19.1% and 16.0%) in the tolvaptan group than in the conventional group, respectively. One of the specific medications indicated worsening-AKI and in-hospital mortality was tolvaptan (odds ratio [OR] 0.155, 95% confidence interval [CI] 0.037–0.657 and OR 0.191, 95% CI 0.037–0.985). The Kaplan-Meier curves showed that the death rate within 6 months was significantly lower in the tolvaptan group. The same result was found after propensity matching of the data. Conclusions: Early administration of tolvaptan could prevent exacerbation of AKI and improve the prognosis for AHF patients. (Circ J 2014; 78: 911–921)<br>
収録刊行物
-
- Circulation Journal
-
Circulation Journal 78 (4), 911-921, 2014
一般社団法人 日本循環器学会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282680085721344
-
- NII論文ID
- 130003391041
-
- NII書誌ID
- AA11591968
-
- COI
- 1:STN:280:DC%2BC2cvmsVGhtg%3D%3D
-
- ISSN
- 13474820
- 13469843
-
- NDL書誌ID
- 025356163
-
- PubMed
- 24553192
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可